The estimated Net Worth of Kurt Wheeler is at least $9.09 million dollars as of 4 January 2016. Kurt Wheeler owns over 15,300 units of Cortexyme Inc stock worth over $115,760 and over the last 18 years Kurt sold CRTX stock worth over $8,975,229.
Kurt has made over 3 trades of the Cortexyme Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Kurt exercised 15,300 units of CRTX stock worth $234,702 on 4 January 2016.
The largest trade Kurt's ever made was buying 1,750,000 units of Cortexyme Inc stock on 29 November 2010 worth over $7,000,000. On average, Kurt trades about 151,149 units every 110 days since 2007. As of 4 January 2016 Kurt still owns at least 59,364 units of Cortexyme Inc stock.
You can see the complete history of Kurt Wheeler stock trades at the bottom of the page.
Kurt's mailing address filed with the SEC is C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET, 54TH FLOOR, BOSTON, MA, 02116.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi et Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: